Skip to main content
Premium Trial:

Request an Annual Quote

Proventys Raises $5.65M in Private Financing; Inks McKesson Alliance

NEW YORK (GenomeWeb News) – Proventys said this week that it has secured $5.65 million in a Series A1 financing led by venture capital firm Burrill & Company.
 
The Durham, NC-based firm also said that it has signed an agreement with healthcare information technology firm McKesson, under which McKesson will incorporate Proventys’ risk prediction modules into its clinical decision support solutions. Concurrent with that agreement, the firm named Marc Owen, executive vice president of corporate strategy and business development at McKesson, to its board of directors.
 
“McKesson is uniquely positioned with proven clinical decision support tools that can provide the ideal platform for bringing Proventys’ advanced knowledge solutions to the point of care where they can make a real difference in clinical decision making and patient outcomes,” Owen said in a statement.
 
Proventys also said that it has named Timothy Thompson, formerly managing director of business development at Aetna, as its new president and CEO. Ralph Snyderman, founder and chairman of the firm, will remain chairman.
 
Proventys is developing risk-prediction tools using clinical data and biomarkers that it believes will enable more effective, targeted approaches to medicine.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.